Prime Medicine Q1 EPS Forecast Raised by HC Wainwright

Prime Medicine, Inc. (NYSE:PRME) – HC Wainwright lifted their Q1 2025 earnings estimates for Prime Medicine in a note issued to investors on Monday, March 3rd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($0.35) for the quarter, up from their prior estimate of ($0.36). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Prime Medicine’s Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.28) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.33) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at ($0.75) EPS.

Other equities analysts have also issued research reports about the company. Citizens Jmp raised Prime Medicine to a “strong-buy” rating in a report on Tuesday, December 10th. Wedbush reissued an “outperform” rating and issued a $12.00 target price on shares of Prime Medicine in a report on Friday, February 28th. Guggenheim reaffirmed a “buy” rating and set a $18.00 price target on shares of Prime Medicine in a report on Tuesday, December 3rd. StockNews.com raised shares of Prime Medicine to a “sell” rating in a research note on Tuesday, February 11th. Finally, JMP Securities assumed coverage on shares of Prime Medicine in a research report on Tuesday, December 10th. They set an “outperform” rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $13.13.

Prime Medicine Price Performance

Shares of NYSE:PRME opened at $2.31 on Thursday. The stock has a market cap of $302.98 million, a P/E ratio of -1.13 and a beta of 1.86. Prime Medicine has a 1-year low of $2.12 and a 1-year high of $8.58. The firm has a fifty day moving average price of $2.82 and a 200 day moving average price of $3.38.

Hedge Funds Weigh In On Prime Medicine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new position in shares of Prime Medicine during the 4th quarter worth approximately $33,000. Nisa Investment Advisors LLC raised its position in shares of Prime Medicine by 11,474.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 12,616 shares of the company’s stock valued at $37,000 after buying an additional 12,507 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Prime Medicine during the 4th quarter worth $42,000. Paloma Partners Management Co acquired a new stake in Prime Medicine in the 3rd quarter worth about $45,000. Finally, AXQ Capital LP acquired a new stake in shares of Prime Medicine in the fourth quarter worth approximately $45,000. Institutional investors and hedge funds own 70.37% of the company’s stock.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.